Antineoplastic and immunomodulating agents | Tenderlake

Antineoplastic and immunomodulating agents

Contract Value:
SEK 148M - 148M
Notice Type:
Contract Notice
Published Date:
07 January 2020
Closing Date:
10 February 2020
Location(s):
SE SVERIGE (SE Sweden/SVERIGE)
Description:
National procurement nab-paclitaxel 2020

Procurement for successive deliveries of the drug nab-paclitaxel (L01CD01) to Sweden's regions. The procurement is carried out by Region Stockholm through the authorization of all other regions.

In this Procurement, agreement is meant to be signed for successive deliveries of the drug nab-paclitaxel (L01CD01) to Sweden's regions. Agreements are entered into with one or more Suppliers. The procurement is carried out by Region Stockholm through the authorization of all other regions. The client does not undertake to call off a certain amount / volume. Calls will be made on the basis of the actual needs of Calling Units, which may, among other things, be affected by new treatment methods and the right of free prescription, and in accordance with ranking.

Download full details as .pdf
The Buyer:
Stockholms läns landsting
CPV Code(s):
33652000 - Antineoplastic and immunomodulating agents